Thursday, 17 December 2020
Investor Ideas #Potcasts #Podcast #509, #Cannabis News and #Stocks on the Move; (NASDAQ: $VFF) (TSXV: $NUMI.V) (NASDAQ: $APHA) (OTCQB: $PHCG) (NYSE: $XXII)
Investor Ideas #Potcasts #Podcast #509, #Cannabis News and #Stocks on the Move; (NASDAQ: $VFF) (TSXV: $NUMI.V) (NASDAQ: $APHA) (OTCQB: $PHCG) (NYSE: $XXII)
Delta, Kelowna, BC, December 17, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/121720-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/12171VFF-NUMI-APHA-PHCG-XXII.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we will be looking at a few private and public company
announcements.
Village
Farms International, Inc. (NASDAQ:VFF) (TSX:VFF) today
announced further expansion of its Cannabis 2.0 offerings,
including its first cannabis-infused gummy products based on the propriety
technology of White Rabbit OG.
Exclusive Partnership with White
Rabbit OG for Edibles Formulation and Manufacture
Pure Sunfarms has entered into an
exclusive partnership agreement with White Rabbit, a BC-based craft cannabis
food formulation and development company, for the formulation and manufacture
of edible cannabis-infused gummies using White Rabbit's proprietary EAT ME
Technology. EAT ME Technology is a proprietary, all-natural emulsion blend that
ensures cannabis extract is dispersed equally in each gummy and increases the
bioavailability of the THC and CBD molecules, allowing for consistent results
and near-perfect dosing. Edibles from both companies will be distributed and
sold by Pure Sunfarms under their respective brands.
Pure Sunfarms and White Rabbit
cannabis-infused gummies are expected to be the only gummies in Canada that are
made using real pure fruit. In addition, they are plant-based, allergen-free,
non-GMO, vegan and preservative-free.
"We are thrilled to exclusively
partner with White Rabbit OG to develop a unique product made with real fruit.
Pure Sunfarms and White Rabbit both share the fundamental belief in providing
consumers with a pure cannabis experience, which we know consumers
appreciate," said Mandesh Dosanjh, President and Chief Executive Officer,
Pure Sunfarms.
"White Rabbit is a true
Canadian leader in the formulation of edibles. Combined with the absorption
benefits of White Rabbit's EAT ME Technology, we see lots of potential in this
rapidly growing segment of the cannabis market."
"As an innovative craft BC
brand, aligning ourselves with a partner who shares our vision and values, sees
the opportunities for growth and is intuitive about what cannabis consumers are
looking for is important to us," said Kyrsten Dewinetz, Co-Founder and
Chief Executive Officer, White Rabbit. "We are excited to have partnered
with Pure Sunfarms, a well-respected, fast-growing licensed producer, whose
approach and commitment to quality is complementary to our own. Together, we
look forward to setting the new standard of cannabis edibles, and delivering
products that not only taste great, but provide consumers with a high-quality
experience."
"This partnership is yet
another example of our' prudent, capital-efficient approach to pursuing growth
opportunities in cannabis," said Michael DeGiglio, CEO, Village Farms
International. "We expect edibles
to be an increasingly meaningful part of the Canadian cannabis market and
exclusively partnering with a formulation and technology leader allows for the
expedited launch of unique products with minimal capital investment."
Pure Sunfarms plans to launch its
Pure Sunfarms-branded cannabis-infused gummies in early 2021, while White
Rabbit plans to launch its brand to the recreational cannabis retail markets in
British Columbia, Alberta, Saskatchewan, and Ontario, as well as nationally
through Medical Cannabis by Shoppers in the coming weeks. White Rabbit's first
products will consist of Craft Blueberry and Craft Sour Peach flavours, each
offered in packs of four 2.5-mg THC per gummy (total of 10-mg THC per pack),
with new flavours and potencies to be added in 2021.
The Pure Sunfarms/White Rabbit
partnership agreement is initially for a period of two years, with the option
to renew the agreement annually thereafter.
Pure Sunfarms Expands Cannabis 2.0
Offering with Launch of High-THC Vapes and Adds New Strains to its Full
Spectrum Vape Collection
Building on the success of its full
spectrum vape products, which were launched in Ontario, British Columbia and
Alberta, Pure Sunfarms will expand its vape product offering with the
introduction of new high-THC vape products in the coming weeks. Each 510
cartridge will feature 840-mg to 900-mg of concentrated THC, intended for
consumers seeking a high-THC experience.
"Our high-THC vape products
have just one ingredient: pure cannabis extract," said Mr. Dosanjh. "They contain no additives, no
alternative botanical ingredients, no flavouring agents, no thinning agents, no
additional cannabinoids. And like all Pure Sunfarms' products, they offer
consumers quality at an attractive price."
Pure Sunfarms will also add two new
strains, Critical Kali Mist and Headband, to their full spectrum vape portfolio
in the weeks ahead.
Numinus
Wellness Inc. (TSXV:
NUMI), a company creating an ecosystem of solutions centred
on the research, development, and delivery of safe, evidence-based, accessible
psychedelic-assisted psychotherapies, has
completed the first legal extraction of Psilocybe
mushrooms in Canada by a public company for research and
development purposes. This follows Numinus' successful completion of the
cultivation and harvest of the first legal flush of Psilocybe mushrooms at Numinus Bioscience, the Company's 7,000
square foot analytics and research laboratory.
"Completing the first legal
extraction of Psilocybe mushrooms in
Canada is a critical next step to providing a natural product for safe,
evidence-based psilocybin-assisted psychotherapies to those in need," said
Payton Nyquvest, CEO, Founder, and Chairman. "Numinus continues to be a
vanguard of positive change for the industry, and this announcement
demonstrates our ability to deliver yet another first."
Numinus Bioscience is establishing
itself at the forefront of analytical testing for psychedelic substances, as a
centre of excellence for psychedelic product research and development, and as
an ancillary for psychedelic therapy clinical trials. Health Canada licences,
scientific expertise, and state-of-the-art technologies facilitate ongoing
innovation, while revenue from high-throughput contract cannabis testing is
reinvested to further its psychedelic initiatives.
"This is an important milestone
in our comprehensive research strategy, following our successful harvest
announced in October," said Sharan Sidhu, Science Officer and General
Manager. "In the extraction process, Numinus Bioscience's goal is to
optimize Psilocybe mushrooms to
standardize psilocybin and multiple therapeutically important components,
increasing the efficacy of the extract. To further our position as a centre of
excellence in the space, we are in the process of submitting amendments to
supply the extract for use in clinical trials and the Special Access Programme,
which, when accepted, will mark a significant move forward in scaling the
delivery of psychedelic-assisted therapies."
"While direct comparisons
cannot be made, there is a clear recognition in the cannabis space that
synthetic cannabinoids are far less attractive than naturally occurring
cannabinoids," indicated Dr. Evan Wood, Numinus' Chief Medical Officer. "Numinus
is of the view that, ultimately, nature knows best, and we're excited to be at
the forefront of exploring the fascinating world of working with Psilocybe mushrooms as part of a focused
drug development program."
This announcement follows Numinus'
advocacy work that contributed to Health Canada's groundbreaking announcement
of its intention to revise the Special Access Programme (SAP) to permit access
to MDMA and psilocybin-assisted psychotherapy in the same way other
investigational medications are accessed in Canada. In addition, earlier this
week Numimius announced the exciting acquisition of Montreal -based Mindspace
Psychology Services Inc (DBA Mindspace Wellbeing) bringing together the
capabilities of two leading Canadian organizations to develop and scale delivery
of evidence-based psychedelic-assisted psychotherapy.
Health Canada's Notice of Intent
regarding the SAP will be open for public consultation and comments for the
next 60 days, and Numinus strongly encourages the community to weigh in on the
benefits of the revision. View the notice here: http://www.gazette.gc.ca/rp-pr/p1/2020/2020-12-12/html/notice-avis-eng.html#nb2.
To share comments and thoughts
related to the SAP, please email hc.csd.regulatory.policy-politique.reglementaire.dsc.sc@canada.ca.
Aphria
Inc. (TSX:
APHA) (NASDAQ:
APHA), a leading global cannabis company
inspiring and empowering the worldwide community to live their best life,
today announced the launch of Broken Coast Cannabis Inc.'s newest innovation and proprietary
strain, Pipe Dream.
With its unique and distinctive
characteristics, which include a bold bud structure, strong smell and look, and
a spicy-gas profile with high THC (18-24%) content, 'Pipe Dream' was ultimately
selected as the newest Broken Coast flower strain after 15-months of careful
testing at its British Columbia-based cultivation facility.
"There aren't many cannabis
plants that are genetically different to what's out there," said Kevin
Anderson, Broken Coast's Head Grower. "To find a plant that scores so high
in all regards of our testing is really one in several hundred - it's very
rare. Pipe Dream is the one in several hundred and we think Canadians will
really love the spicy and gassy profile, as it's truly different to anything
else in our current strain offering but still the high-quality product
consumers have come to expect from Broken Coast."
To unearth a cultivar worthy of the
Broken Coast brand required the master grow team to plant, nurture and evaluate
thousands of seedlings, seeking to identify and accentuate the traits that
produce a truly exceptional smoke. Some felt a flower this special was nothing
but a Pipe Dream. Now Canadians can decide for themselves.
Pipe
Dream has
a very dense and round bud structure thickly covered with bright trichomes. The
lime green and purple flower also has a touch of fruitiness within its spicy
and pungent profile. Pipe Dream is
available in BC in 3.5g whole flower online and in retail and will be rolling
out to the rest of the country (except for Quebec) over the next few months. In
addition, 5g and 10g formats are also available to medical clients.
This is the second innovation
recently launched by Broken Coast, following the recently announced expansion
of its product portfolio and entry into the 2.0 market with the launch of 510
vapes.
Pure
Harvest Corporate Group, Inc. (OTCQB:
PHCG), a publicly-traded holding company focused on
emerging and high-growth industries, announced the
development of a cannabinoid compound which the Company believes has numerous
applications as a versatile product ingredient. The working name for the
cannabinoid compound is “Complex 612.”
“Complex 612 is a patent pending
formulation created through extracting and compressing specific compounds
within the hemp plant. Together with the addition of an antioxidant synergist
to augment bioavailability and predictably of the experience in the ‘vehicle’
it is utilized within traditional, functional foods, confections, and
beverages. Complex 612 also serves as a catalyst when paired with a variety of
active compounds from plants including mushrooms, adaptogens, nootropics and
others,” said Dr. James Rouse, NMD, Test Kitchen Chief Formulator. “The possibilities
are limitless.”
“We believe Complex 612 and the wide
variety of products and product enhancements that will come from it will be a
game changer for the Company and this industry,” stated Matthew Gregarek, CEO,
Pure Harvest Corporate Group. “We are already far down the road in our product
development and planned roll-out and we are extremely excited to bring this
product to market.
“Renowned cannabis attorney Donnie
Emmi will officiate the product development and launch as CEO of our wholly owned
subsidiary Test Kitchen and world-class marketing consultants Shipyard are
handling everything from branding to our go-to-market strategy.
“I believe that I have truly
assembled an All-Star team worthy of this tremendous innovation and am so
immensely proud of what we’ve done and excited about what the very near future
holds for Pure Harvest and its shareholders,” added Gregarek.
22nd
Century Group, Inc. (NYSE:
XXII), a leading plant-based, biotechnology company focused
on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis
research, announced
today that it was granted a new U.S. patent related to the
control of cannabinoid and terpene production in plants. This new intellectual
property exclusively provides 22nd Century with unique and powerful tools to
alter the cannabinoid biosynthesis pathway in hemp/cannabis plants.
"We are delighted to receive
this patent, which is the result of work carried out by our own scientists.
This important, new technology will allow us to genetically modify
hemp/cannabis plants to modulate their cannabinoid and terpene profiles in
order to tailor these plants’ therapeutic qualities and enhance the consumer’s
hemp/cannabis experience," said Juan Sanchez Tamburrino, Ph.D., vice
president of research & development at 22nd Century Group. "Our patent
application describes eight promoters, which are essentially molecular on/off
switches, covering all of the major steps in the cannabinoid biosynthesis
pathway. Typically, developing hemp/cannabis plants with new cannabinoid or
terpene profiles could take 10 to 20 years using traditional breeding methods.
Now, with the combined technologies and know-how of 22nd Century and KeyGene,
we expect to shorten the development timeline to create new, differentiated,
hemp/cannabis plant lines in just 4 to 5 years. Doing so will provide the
Company and its potential licensees and customers with significant competitive advantage
as hemp/cannabis continues to penetrate the life science, consumer product, and
pharmaceutical markets.”
“At 22nd Century Group, we take a
scientific and solutions-oriented approach to advancing ground-breaking,
plant-based technology. We are excited to secure this patent, and we believe
that it demonstrates our unique and leading role in plant science innovation
within the $100 billion global hemp/cannabis market,” said James A. Mish, chief
executive officer of 22nd Century Group.
The new patent, published as U.S.
Patent No. 10,787,674 B2 and entitled "Trichome specific promoters for the
manipulation of cannabinoids and other compounds in glandular trichomes,"
enables 22nd Century to develop and deliver new hemp/cannabis plants that are
designed to produce cannabinoids more efficiently. The Company can potentially
increase the yield of plants, stabilize the level of cannabinoids that are
produced, and create custom cannabinoid profiles optimized for specific
therapeutic uses. 22nd Century will also be able to potentially modulate the
terpene levels within the plant – increasing them to deliver new strains of
cannabis for the adult-use/recreational market and reducing them to remove the
odor and taste for improved application in foods and beverages.
Cannabinoids, such as CBD, CBC, and
CBG, are valuable compounds that hold great promise for the development of new
medicines and other therapeutic applications. Cannabis sativa is the only plant species that produces significant
amounts of these compounds including more than one hundred different
cannabinoids in varying quantities. In nature, cannabis plants restrict
production of these potentially toxic compounds to the trichomes which are tiny
hair-like stems and globes that grow on the surface of the plant. To
successfully manipulate cannabinoids, the Company’s new technology activates
molecular promoters, “on/off switches,” specifically
and only in the plant’s trichomes where the majority of cannabinoids are
produced. These regulatory sequences dynamically enhance or restrict gene
expression levels, controlling the expression of genetic information that leads
to the production of cannabinoids.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Investors can trade these stocks and other ideas on our site using
our list of top
stock trading apps including Robinhood, Acorn, Stash and
others.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Wednesday, 16 December 2020
Investor Ideas #Potcasts Episode 508, #Cannabis News and #Stocks on the Move; (TSX: $APHA.TO) (NASDAQ: $APHA) (NASDAQ: $TLRY) (OTC: $EDXC) (OTCQX: $INLB)
Investor Ideas #Potcasts Episode 508, #Cannabis News and #Stocks on the Move; (TSX: $APHA.TO) (NASDAQ: $APHA) (NASDAQ: $TLRY) (OTC: $EDXC) (OTCQX: $INLB)
Delta, Kelowna, BC, December 16, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/121620-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/12161APHA-TLRY-EDXC-INLB.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we will be looking at a few private and public company
announcements.
Aphria Inc. (TSX:
APHA) (Nasdaq:
APHA), a leading global cannabis company
inspiring and empowering the worldwide community to live their very best life,
and Tilray, Inc. (Nasdaq:
TLRY), a global pioneer in cannabis research,
cultivation, production and distribution, today
announced that they have entered into a definitive
agreement to combine their businesses and create the world’s largest global
cannabis company based on pro forma revenue. The deal is pursuant to a plan of
arrangement under the Business
Corporations Act (Ontario), and the implied pro forma equity value of the
Combined Company is approximately C$5.0 billion (US$3.9 billion), based on the
share price of Aphria and Tilray at the close of market on December 15, 2020.
Following the completion of the Arrangement, the Combined Company will have
principal offices in the United States (New York and Seattle), Canada (Toronto,
Leamington and Vancouver Island), Portugal and Germany, and it will operate
under the Tilray corporate name with shares trading on NASDAQ under ticker
symbol "TLRY".
The Combined Company,
supported by low-cost, state-of-the-art cultivation, processing, and
manufacturing facilities, will have a complete portfolio of branded Cannabis
2.0 products in Canada. Internationally, the Combined Company will be
well-positioned to pursue growth opportunities with Aphria’s medical cannabis
and distribution footprint in Germany, and Tilray’s European Union Good
Manufacturing Practices low-cost cannabis production facility in Portugal,
which has export capabilities and tariff-free access to the European Union to
meet increasing global demand for medical cannabis. In the United States, the
Combined Company will have a strong consumer packaged goods presence and
infrastructure with two strategic pillars, including SweetWater Brewing
Company, a cannabis lifestyle branded craft brewer, and Manitoba Harvest, a
leading hemp food manufacturer and a pioneer in branded CBD and wellness
products. The Combined Company is expected to have a strong, flexible balance
sheet, cash balance and access to capital giving it the ability to accelerate
growth and deliver attractive returns for stockholders.
Under the terms of the
Arrangement, the shareholders of Aphria will receive 0.8381 shares of Tilray
for each Aphria common share, while holders of Tilray shares will continue to
hold their Tilray shares with no adjustment to their holdings. Upon the
completion of the Arrangement, Aphria Shareholders will own approximately 62
percent of the outstanding Tilray Shares on a fully diluted basis, resulting in
a reverse acquisition of Tilray, representing a premium of 23 percent based on
the share price at market close on December 15, 2020 to Tilray shareholders. On
a pro forma basis for the last twelve months reported by each company, the
Combined Company would have had revenue of C$874 million (US$685 million).
The Combined Company
will be led by a best-in-class management team and board of directors, with
strong track records in consumer-packaged goods and cannabis experience
internationally. Upon completion of the Arrangement, Aphria’s current Chairman
and Chief Executive Officer, Irwin D. Simon, will lead the Combined Company as
Chairman and Chief Executive Officer. The board of directors will consist of
nine members, seven of which, including Mr. Simon, are current Aphria directors
and two of which will be from Tilray, including Brendan Kennedy, and one of
which is to be designated. Aphria and Tilray are confident that the leadership
team and proposed board of directors of the Combined Company provides a strong
foundation for the Combined Company to accelerate growth. Additional senior
leadership positions at the Combined Company will be named at a later date.
"This is an
exciting day for both companies including our 2,500 employees, for the cannabis
industry, and for patients and consumers around the world. We are bringing
together two world-class companies that share a culture of innovation, brand
development and cultivation to enhance our Canadian, U.S., and international
scale as we pursue opportunities for accelerated growth with the strength and
flexibility of our balance sheet and access to capital," said Mr. Simon.
"Our highly complementary businesses create a combined company with a
leading branded product portfolio, including the most comprehensive Cannabis
2.0 product offerings for patients and consumers, along with significant
synergies across our operations in Canada, Europe and the United States. Our
business combination with Tilray aligns with our strategic focus and emphasis
on our highest return priorities as we strive to generate value for all stakeholders."
"I am honored to
work with Brendan Kennedy, a pioneer in the cannabis industry, and the Tilray
team as they join forces with our talented employees at Aphria," continued
Mr. Simon. "I look forward to leading the talented teams of both Aphria and
Tilray as we seek to create a leading global cannabis and consumer packaged
goods company with a portfolio of medical, wellness and adult-use brands
consumers love."
Mr. Kennedy, Tilray’s
Chief Executive Officer, commented, "We are thrilled to bring together two
cannabis industry leaders. At this nascent stage of development and expansion
of the global cannabis market, we believe companies with leading geographic
scale, product range and brand expertise are most likely to benefit long-term.
By leveraging our combined strengths and capabilities, we expect to be able to
meet the needs of consumers more effectively all over the world and advance
patient care. With a strong financial profile, low-cost production, leading
brands, distribution network and unique partnerships, we believe the Combined
Company will be well-positioned to deliver sustainable, attractive returns for
stockholders. I look forward to working with Irwin and the Combined Company’s
management team to make our consumer products more accessible around the
world."
Emerald
Bioscience, Inc. (OTCQB:
EMBI), a preclinical biopharmaceutical company focused on
developing proprietary molecules with strong clinical and commercial
differentiation, announced
the publication of a peer-reviewed paper reporting that
THCVHS, the Company’s novel THC prodrug, was optimized through a nanoemulsion
formulation (THCVHS-NE) for drug delivery into the eye and demonstrated
significantly better reduction of intraocular pressure (IOP) compared to the
commercially approved standard of care in normotensive rabbits.
Response was determined by measuring
reduction in IOP from baseline following a single treatment with either
THCVHS-NE (1% w/v), latanoprost (0.005% w/v), or timolol (0.25% w/v), which was
measured every 30 minutes post-treatment up to 180 minutes, followed by
measurements at 240, 360 and 480 minutes post-treatment. Duration of response
was determined as the time required for IOP to return to 90% of baseline.
THCVHS-NE achieved a maximum drop in IOP of 23% compared to latanoprost (13%)
and timolol (14%). In addition, duration of response for THCVHS-NE was ≤480
minutes, compared to latanoprost (≤360 minutes) and timolol (≤90 minutes)
(p<0.05) in normotensive rabbits. Therefore, a nanoemulsion formulation of
THCVHS appears to not only be more effective at reducing IOP, but also has a
longer duration of response when compared to standard of care treatment for
glaucoma.
The article, entitled “Effect of
surfactant concentration and sterilization process on intraocular
pressure–lowering activity of Δ9 ‑tetrahydrocannabinol‑ valine‑hemisuccinate (NB1111) nanoemulsions,”
authored by Sweeney, C., Dudhipala, N., Thakkar, R. et al, was published in the November 2020
issue of Drug Delivery and Translational
Research. The experiments were conducted by researchers at the University
of Mississippi.
“Our aim is to be able to offer
ophthalmologists and their patients a superior new class of treatment for
glaucoma, with better intraocular-pressure-lowering activity to prevent vision
loss. The intriguing scenario is that THC’s ability to lower intraocular
pressure is already validated – we know it works, based on prior human studies!
We also know, however, that to successfully employ THC as a good medicine for
glaucoma we need to have an effective method of local delivery into the eye,
consistent with the American Academy of Ophthalmology’s recommendation against
systemic use of cannabis to manage glaucoma. This is precisely what our drug
offers,” said Punit Dhillon, CEO of Emerald.
“What is additionally and
particularly notable is that our unique, synthetic bioengineered THCVHS
molecule has potential capabilities that current treatments are unable to
provide. A large percentage of glaucoma patients do not experience increased
IOP but nevertheless experience vision loss believed to result from other
neurodegenerative effects on the cells of the optical nerve. THC is also known
to have neuroprotective properties. If our drug can protect against vision loss
in patients with normal IOP as well, we would have an extraordinary new
solution to offer for the prevention of glaucoma-related vision loss.
“We are working to complete our
preclinical work in the near term and then start our planned human study in the
third quarter of 2021. The nature of this disease will allow us to
simultaneously provide safety and early efficacy outcomes in a first human
study that is relatively fast and low-cost compared to the typical realization
of such results in the clinical trial process,” added Mr. Dhillon.
Endexx
Corporation (OTC:
EDXC): Music
magnate, mega producer and GRAMMY® Award-winning artist DJ Khaled announced his
entrance into the CBD industry. Inspired by his personal wellness journey,
Khaled, in partnership with Endexx, a leading producer and manufacturer of
hemp-derived CBD wellness products, will introduce his new company and debut
the first collection in 2021.
Although most well-known for his
contributions to the music world, the self-made businessman turned
international music icon is also a dedicated family man -- committed to
instilling the importance of health and wellness into everyday life. Grateful
to be a father, he released two albums in honor of his children, Father of Asahd in 2019 and Grateful in 2017. With all of these
blessings, Khaled continues building his legacy and success by focusing his
energies on the health and wellness sector.
“As a father, an entrepreneur, a
music exec and visionary I am blessed with daily inspiration, a drive to work
hard and a passion for success. CBD has
become a part of my daily routine and allows me to focus myself and my
energies, while striving to better myself every day,” says DJ Khaled. “I was drawn to Endexx Corporation because
they're an innovative company that has proven they have the keys to deliver
consistent, top of the line, high-quality products.”
“We are excited to announce our
partnership with DJ Khaled,” stated Todd Davis, CEO of Endexx Corporation.
“Khaled’s knowledge and passion for CBD is bountiful and we realized we are
aligned in our approach towards product quality and business acumen. We understand and share the values that a
brand goes beyond physical products; it needs to help people feel good about
themselves and be part of a day-to-day lifestyle.”
Miami based IMPACT Brokers, the
third party in the joint venture, will be spearheading sales and integrated
marketing efforts on behalf of the brand. “We are committed to accelerating
innovation and diversity throughout this developing industry while offering
strategic guidance to best-in-class CBD suppliers. IMPACT Brokers sits at the forefront of
culture and has the ability to predict industry trends. We look forward to taking this newest
business nationwide,” says Ryan Stender, CEO of IMPACT Brokers.
The hemp-derived, cannabidiol-rich
collection is anticipated to launch in early 2021.
Item
9 Labs Corp. (OTCQX:
INLB), a vertically integrated cannabis operator that
produces premium products, announced
today that it has finalized its merger agreement with ONE
Cannabis Group (OCG, Inc.) and expects to close the merger in January 2021.
ONE Cannabis Group, based in
Colorado, is the parent company to the cannabis dispensary franchise Unity Rd.
Built up from the legacy of a 10-plus year, award-winning Colorado dispensary
& cultivator and infused with decades of franchise experience, the company
helps eager operators enter the complex industry with ease. The cannabis franchise
pioneer offers its partners the knowledge, resources, and ongoing support
needed to compliantly and profitably operate a dispensary. Currently, Unity Rd.
has franchise agreements signed for the development of more than two dozen
shops across multiple states and expects the first store to open in quarter one
2021.
Recently, it was named one of the
top cannabis retail leaders in the nation by MJBizDaily magazine and one of the "Best Cannabis Companies to
Work For" in both the dispensary and cultivation categories in Cannabis
Business Times' elite 2020 list. The company is also the first cannabis
business to earn a Franchise Times
Dealmakers award – a recognition presented to the boldest players driving
mergers and acquisitions in franchising. For more information on ONE Cannabis
Group, visit ocginc.com and head to unityrd.com for details on the Unity Rd.
franchise opportunity.
"Our teams have been working on
parallel paths to ensure a smooth integration and are eager to officially
operate as one unit. This was a significant milestone for all and we look
forward to closing [the merger] in January 2021," Item 9 Labs' Chief
Executive Officer, Andrew Bowden, commented. "The merger with ONE Cannabis
Group greatly enhances our business capabilities with its retail distribution
and unique franchise operation. Their business model and national network of
Unity Rd. franchise partners create highly predictable, recurring revenue
streams."
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Investors can trade these stocks and other ideas on our site using
our list of top
stock trading apps including Robinhood, Acorn, Stash and
others.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news,
articles, podcasts and
stock directory
Subscribe to:
Posts (Atom)
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ... -
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...
-
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: Dixie Brands (CSE: $DIXI_U.C) (OTC: $DXBRF), Khiron Life Sciences (T...